Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.56 |
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14765263 | 1.00 | SLC17A5 (0.56) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL2419146 | 1.00 | SLC17A5 (0.56) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL19888241 | 0.90 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL161752 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL161749 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL161751 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL161750 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL14765032 | 0.87 | MDM4 (0.47) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL29386847 | 0.86 | SLC17A5 (0.44) | SLC17A5MDM4TP53CASP3KMT2A | |
| SCHEMBL1486194 | 0.86 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728289-B1 | OPTIMISED COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2025-09-10 | — | — | EP | disclosed |
| US-20250066416-A1 | OPTIMISED COMPOUNDS | THE UNIVERSITY OF MELBOURNE (AU) | 2025-02-27 | — | — | US | disclosed |
| US-12195557-B2 | Optimised compounds | Axelia Oncology Pty Ltd (AU) | 2025-01-14 | — | — | US | disclosed |
| CN-118161614-A | Treatment of respiratory tract infections with TLR2 agonists | 艾娜呼吸私人有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3600374-B1 | TREATMENT OF RESPIRATORY INFECTION | Ena Respiratory Pty Ltd (AU) | 2024-05-15 | — | — | EP | disclosed |
| CN-110461351-B | Treatment of respiratory tract infections with TLR2 agonists | 艾娜呼吸私人有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20210230217-A1 | OPTIMISED COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2021-07-29 | — | — | US | disclosed |
| US-20210177795-A1 | ADMINISTERING COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2021-06-17 | — | — | US | disclosed |
| EP-3728289-A1 | OPTIMISED COMPOUNDS | Ena Therapeutics Pty Ltd (AU) | 2020-10-28 | — | — | EP | disclosed |
| EP-3727372-A1 | ADMINISTRATION OF A TLR2 AGONIST FOR THE TREATMENT OR PREVENTION OF A RESPIRATORY CONDITION ASSOCIATED WITH AN INFECTIOUS AGENT | Ena Therapeutics Pty Ltd (AU) | 2020-10-28 | — | — | EP | disclosed |
| EP-1546206-A4 | NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND CYTOTOXIC T LYMPHOCYTE (CTL) EPITOPES | QUEENSLAND INST MED RES (AU) | 2007-10-10 | — | — | EP | disclosed |
| EP-1543039-A4 | NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND B-CELL EPITOPES | QUEENSLAND INST MED RES (AU) | 2007-09-19 | — | — | EP | disclosed |
| US-20070160631-A1 | Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20070066534-A1 | Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-03-22 | — | — | US | disclosed |
| WO-2006084319-A1 | IMMUNOGENIC MOLECULES | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006021048-A1 | IMMUNOTHERAPY OF VIRUS INFECTION | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED (AU) | 2006-03-02 | — | — | WO | disclosed |
| EP-1546206-A1 | NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND CYTOTOXIC T LYMPHOCYTE (CTL) EPITOPES | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-06-29 | — | — | EP | disclosed |
| EP-1543039-A1 | NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND B-CELL EPITOPES | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004014957-A1 | NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND CYTOTOXIC T LYMPHOCYTE (CTL) EPITOPES | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014956-A1 | NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING T-HELPER AND B-CELL EPITOPES | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160631-A1 | Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes | LY96, LTA, CD4 | SLC17A5 1730/4885MDM4 2025/4885TP53 113/4885 |
| US-20210230217-A1 | OPTIMISED COMPOUNDS | TLR2, TLR3, TLR1 | SLC17A5 1409/4885MDM4 4271/4885TP53 2503/4885 |
| US-20250066416-A1 | OPTIMISED COMPOUNDS | TLR2, TLR3, TLR1 | SLC17A5 1409/4885MDM4 4271/4885TP53 2503/4885 |
| US-12195557-B2 | Optimised compounds | TLR2, TLR3, TLR1 | SLC17A5 1409/4885MDM4 4271/4885TP53 2503/4885 |
| US-20070066534-A1 | Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes | CD4, LY96, CD69 | SLC17A5 1242/4885MDM4 4033/4885TP53 819/4885 |
| US-20210177795-A1 | ADMINISTERING COMPOUNDS | TLR2, TLR3, TLR5 | SLC17A5 400/4885MDM4 3602/4885TP53 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.